GSK 2831781

Drug Profile

GSK 2831781

Alternative Names: GSK2831781; IMP-731

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immutep
  • Developer GlaxoSmithKline
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T lymphocyte inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Plaque psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Plaque-psoriasis in Germany (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Plaque-psoriasis in United Kingdom (IV, Infusion)
  • 08 Sep 2017 Prima BioMed receives patent allowance for IMP 731 (GSK 2831781) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top